Biomarkers /
GEN1
Overview
GEN1 is altered in 1.95% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, glioblastoma, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in GEN1 are GEN1 Mutation (1.66%), GEN1 Nonsense (0.13%), GEN1 Amplification (0.06%), GEN1 T765S (0.06%), and GEN1 Deletion (0.05%) [3].
Clinical Trials
Significance of GEN1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.